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A.12 ABSTRACTS 
of respiratory distress and improvement of roentgenographic changes) was seen in group B. There were no side effects after 
methylprednisolon treatment. 
Conclusion: the clinical efficiency of treatment with methylprednisolon may be considered established in the treatment of 
severe pneumonia. 
17. Chlamyda pneumoniae infection in COPD patients with acute exacerbation 
D. KARNAK*,S.BENGISLJN**,S.BEDERANDO.KAYACAN* 
Ankara University Medical Faculty, “Department of Chest Diseases and Tuberculosis, 
**Laboratory of Bacteriology, 06100 Cebeci-Ankaral, Turkey 
Our aim was to investigate the possible association of Chlamydia pneumoniae (Cpn) infection with acute exacerbation in 
COPD patients. For this purpose, 38 COPD patients who had acute exacerbations of respiratory conditions and 17 healthy 
smokers without respiratory disease were enrolled in the study, as study and control groups respectively. Nasopharyngeal 
swabs and paired serum samples were obtained from all subjects for antibody testing of Cpn. Sputum cultures of COPD 
patients were also performed. No pathogenic bacteria were isolated from nasopharyngeal swabs in any subject. IgM antibody 
which is a serologic evidence of recent Cpn infection was observed in 15 COPD patients (39%) and one control subject (0.5%). 
The prevalence of Cpn IgG antibodies were significantly higher in COPD patients than in control subjects (PcO.05). 
Prevalence of IgA antibodies did not show difference between two groups (P>O.O5). Microbiologic culture of the sputa 
yielded potentially pathogenic microorganisms in 23 of 38 COPD patients (60%). S. pneumoniae (4%) H. influenza (4%), 
a-hemolytic streptococcus (35%), Niesseria spp (30%), Candida spp (9%) S. aureus (4%), l? aeruginosa (4%) were isolated. 
Although a high prevalence of IgG antibodies against Cpn was detected in COPD patients, Cpn was the sole causative agent 
in only 4 patients (10%). We conclude that most patients with COPD are chronically infected with Cpn and it may either be 
the only causative agent or a co-agent in the acute exacerbation. 
18. Clinical outcome of community-acquired pneumonia (CAP) in hospitalized 
patients. Experience from the central Moravia 
V. KOLEK, H. FOJT~, M. KOLARAND I. VAGNEROVA 
Dept. of Pulmonary med. and Microbiology, University Hospital, Olomouc, Czech Republic 
Present work evaluates 101 consecutive cases of CAP from the central Moravia hospitalized in the pulmonary department 
from 1996 to 1999. Before hospitalization 63 patients were treated with one or more antibiotics: penicillins ( 38%), macrolides 
(28%), cotrimoxazol (9%) and cephalosporins (2%). Risk factors were as follows: infiltration greater than one lobe (57 pts), 
age older than 60 (52 pts), pleural reaction (44), considerable changes in vital signs (30) polymorbidity (16), hemoptysis (lo), 
mental alteration (10) and cavitation on the chest X-ray in 8 pts. There was hypoxemia in 84 pts, hypercapnia in 13, 
leucocytosis above 20 000 in 8 and bacteremia in 6 pts. The mean length of symptom duration was 8.4 days, the mean length 
of stay in hospital was 18.9 days. Recognized pathogens were: C. pneumoniae (19), H. infuenzae (16), Enterobact. sp. (15) 
M. pneumoniae (1 l), S. pneumoniae (lo), K. pneumoniae (9). In the oral treatment fluorochinolons (23.1%), penicillins (22.2%), 
tetracyclines (21.9%) antimycotics (12.1%), cephalosporins (11.6%) and macrolides (4%) were used. Parenteral treatment was 
realized by penicillins (45.3%), cephalosporins (33.7%) and aminoglycosides (14.5%). There were 9 cases of empyema, 4 cases 
of lung abscess, 6 patients were referred to ICU and 3 died. In the follow up 37 patients suffered from functional respiratory 
impairment. 
19. Moxifloxacin susceptibility program (MSP): national and regional in vitro 
susceptibility of common respiratory tract pathogens 
S.KOWALSKY,R.PRYKA, J. HARRIS,K.GRAVELLE,B.PAINTERANDTHE MSP STUDYGROUP 
The Moxifloxacin Susceptibility Program (MSP) was initiated to test the susceptibilities of common respiratory tract 
pathogens against commonly prescribed antimicrobials including the new 8-methoxyfluoroquinolone, moxifloxacin. The 
comparative agents tested were trovafloxacin, levofloxacin, penicillin, cefuroxime, amoxicillin/clavulanate, azithromycin, and 
trimethoprim-sulfamethoxazole. Fresh and/or frozen clinical isolates were collected from July 1998-November 1999. 
Organisms included Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus injluenzae, Moraxella catarrhalis, and 
Klebsiella pneumoniae. The data collected included clinical source (blood/sputum) of the isolate, clinical location (community 
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or hospital), and the MICs as determined by the broth microdilution method. In this preliminary analysis of 39 sites across 
the US, the non-susceptibility of S. pneumoniue to penicillin closely matched that of recent national surveillance studies with 
intermediate non-susceptibility of 31% and high-level penicillin resistance of 14%. Among the antibiotics tested, the 
quinolones were the most active; against S. pneumoniae, moxifloxacin was more active than trovafloxacin, which was more 
active than levofloxacin. These data outline an effective approach to generating comparative regional and national 
susceptibility data against the common respiratory tract pathogens. 
20. Chlamydia pneumoniae infection in community aquired pneumonia (CAP) 
patients in Tartu 
H. LILL, H. LEESIK AND E. LAJA 
Tartu University Lung Hospital, Estonia 
Aims: The aim of the study was to verify the role of Chlamydia pneumoniae in the aethiology of CAP 
Material and method: we prospectively analyzed case histories, medical records and investigations of Chlamydia pneumoniae 
antibodies in 70 hospitalized CAP patients (mean age 48 yrs.) in the Tartu University Lung Hospital in 1999. Clamydia 
pneumoniae antibodies were measured by ELISA method and the results were presented in enzyme immune units (EIU). The 
signs of acute infection (IgA>8, and/or positive IgMr1.1, IgGs30 EIU) were found in 44 patients (63%), (mean age 52 yrs.) 
The mean value for IgA was 41.9 EIU (ranging from 10 to 179), and for IgG 132.3 EIU (ranging from 31 to 383.8). 26 
patients (mean age 40 yrs.) did not satisfy the criteria of Chlumydia pneumoniae infection. There were no Chlamydia 
pneumoniue antibodies in 19 (27%) of patients, IgG antibody was identified in 7 (10%) of patients. 
A second concurrent respiratory pathogen (Mycoplasma pneumoniae, B. pertussis or other typical bacteria) was found in 17 
(39%) acute Chlamydiapneumoniae cases. All patients predominately suffered from acute clinical symptoms. 
In conclusion: Chlamydia pneumoniae is an important aethiological agent in hospitalized CAP patients in our hospital, mainly 
in patients 50 years and over. 
21. Community acquired pneumonia (CAP&diagnostic relevance of bronchoalveolar 
lavage (BAL) 
M. KUREPKAT, M. RAFFENBERG”, H. MAUCH+ AND H.LoDE* 
*Department of Chest and Infectious Diseases and tlnstitute for Medical Microbiology, Chest Hospital 
Heckeshorn, Berlin, Germany 
Quantitative BAL is an accepted diagnostic tool in nosocomial and ventilator associated pneumonia-the position of this 
bronchoscopic technique in CAP however is unclear. Between 1992 and 1996 149 patients (68.5% males) with finally 
diagnosed CAP underwent BAL. BAL passed for positive if the following criterias were fulfilled: 104 cfu/ml or qualitative 
proof of P carinii. A positive bacteriological diagnosis by BAL was possible in 48.3% of these patients. Leading pathogens 
were Gram-positive cocci (14.8%) and l? carinii (14.8%) followed by H. inzuenca (9.4%). A previous antibiotic therapy did not 
reduce positive BAL results (47.3% vs. 50.0%). Complications of bronchoscopy were temporary. Results of BAL induced a 
change of antibiotic treatment in 85.0% of patients with positive BAL findings. Quantitative BAL contributes significantly to 
a precise diagnosis and treatment of CAP 
22. Fluoroquinolone kill against Streptococcus pneumoniae 
J. GEORGE AND I. MORRISSEY 
GR Micro Ltd, London, UK. 
The bactericidal activity of the fluoroquinolones (FLQs) levofloxacin (LEV), ciprofloxacin (CIP), ofloxacin (OFL), 
moxifloxacin (MOX) or grepafloxacin (GRE) between 0.003 and 200 mg/l was assessed in Mueller Hinton broth (& 5% (v/v) 
lysed horse blood) over 3 h at 37 “C. Three penicillin-susceptible clinical isolates of S. pneumoniae (SP) were used; SP 007 
(OFL MIC 1 mg/l); SP 303 (OFL MIC 4 mg/l) and SP 181 (OFL MIC 32 mg/l). After incubation, viable counts were made on 
blood agar and log change in viability was plotted against log drug concentration. Kill was compared relative to individual 
drug pharmacokinetics by calculating bactericidal indices (BIs) from these plots (J Antimicrob Chemother 1997, 39: 713). BIs 
were calculated as the AUC of each kill curve at bactericidal concentrations up to serum Cmax (Smax) or lung tissue Cmax 
(Lmax) using data from published literature after single 400 or 500 mg oral doses. 
